Over 1 million people with weakened immune systems can improve protection against COVID-19 by pausing their medication for 2 weeks after their booster jab.
The findings are part of the ongoing REMAP-CAP trial which is funded and supported by NIHR.
NIHR Applied Research Collaborations (ARCs) have launched a report looking at their contribution to the fight against COVID-19.
It will find out if antibody testing can identify which immunosuppressed people remain at greatest risk of severe COVID-19 infection after vaccinations.
The REMAP-CAP study is funded and delivered by NIHR and aims to use pandemic lessons to find effective treatments for people hospitalised with severe flu.
The HEAL-COVID study has found that a drug used to reduce the risk of blood clots does not help patients recovering from moderate and severe COVID-19.
A new NIHR funded study of 57 people with mild COVID-19 estimates how long people are infectious for and when they can safely leave isolation.
NIHR-supported Moderna Omicron bivalent COVID-19 vaccine booster receives UK approval from MHRA
People in England continued to feel distressed even after all legal COVID-19 restrictions ended in February 2022, suggests new research funded by the NIHR.
A study funded by NIHR and UK Research and Innovation has found that people with long COVID experience a wider set of symptoms than previously thought, including hair loss and sexual dysfunction.
Preg-CoV, a COVID-19 vaccine study, is calling on pregnant women to join hundreds of volunteers and help researchers find the most effective use of boosters.
Women, people aged 50-60, and people with poor pre-pandemic mental or physical health are more at risk of long COVID, according to research funded by the NIHR and UK Research and Innovation.
Interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination can double their antibody response to the jab, new research finds.
A standard two-dose Pfizer-BioNTech or Oxford-AstraZeneca vaccine schedule showed a greater antibody increase when given at a 12-week interval, compared to a four-week interval.
An NIHR-supported study of more than 28,000 people has shown that vaccination against COVID-19 is associated with a moderate reduction in the risk of experiencing long COVID.
Com-COV 3 to test multiple options for third booster dose COVID-19 vaccines for young people aged 12 to 15 years old
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from the NIHR-supported COV-BOOST study.
Researchers have worked with patients to develop a comprehensive tool to assess the symptoms of long COVID and their impact on everyday life.
The latest results from the UK’s COV-BOOST study, led by University Hospital Southampton, have shown prolonged immune responses following third doses of several COVID-19 vaccines.
Following rigorous clinical trials supported by the NIHR and thorough data analysis, the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the Valneva COVID-19 vaccine for UK use.
The NIHR-supported PANORAMIC trial is investigating a new COVID-19 antiviral treatment, Paxlovid, among vulnerable groups in the community.
The world’s largest study of the genetics of critical COVID-19, has revealed details about some of the biological mechanisms behind the severe form of the disease
The NIHR-supported RECOVERY trial has found that baricitinib, an anti-inflammatory rheumatoid arthritis drug, reduces deaths in patients hospitalised for COVID-19 by around one-fifth.
One of the world’s first Omicron-specific COVID-19 variant vaccines is to be trialled at multiple sites across the UK, as the biotechnology company Moderna, Inc works alongside the NIHR.
Researchers have developed new definitions for what long COVID is and the key effects in children and adults, which will help harmonise research and improve understanding of the condition.
